We are a clinical-stage pharmaceutical company focused on the discovery and development of human therapeutics to fill unmet medical needs. In 2008, TransTech Pharma, Inc. spun off certain of its assets into High Point Pharmaceuticals, LLC. Since that time we have acquired certain additional drug development programs from TransTech. We have a contract with TransTech for the use of its facilities and access to personnel for the continued discovery and development of our drug candidate programs.
We have a pipeline of small molecule clinical and pre-clinical drug candidates for the treatment various human diseases with a focus on central nervous system disorders, diabetes, and the complications associated with diabetes such as obesity, dyslipidemia and glaucoma.